Breast Cancers Today Videos

Advertisement
Rupert Bartsch, MDHER2 Breast Cancer | June 5, 2025
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.
Sara Tolaney, MD, MPHTriple-Negative Breast Cancer | June 5, 2025
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Erika P. Hamilton, MDHR Breast Cancer | June 5, 2025
Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 4, 2025
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Stephanie L. Graff, MDHER2 Breast Cancer | June 4, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
Eva Blondeaux, MDGenetics & Breast Cancer | May 22, 2025
Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
Eva Blondeaux, MDGenetics & Breast Cancer | May 22, 2025
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients.
Antonio Llombart Cussac, MD, PhDHR Breast Cancer | May 14, 2025
PALMIRA trial shows limited benefit of palbociclib rechallenge in HR+/HER2- breast cancer, guiding future treatment choices.
David Winchester, MDBreast Cancer News | May 10, 2025
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
David Winchester, MDBreast Cancer News | May 5, 2025
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 1, 2025
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 6, 2025
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Dr. Sadie Dobrozsi, EvolentGenetics & Breast Cancer | March 26, 2025
Dr. Sadie Dobrozsi spoke on the importance of genetic testing in breast cancer to better understand the disease.
Leah Pyter, PhDBreast Cancer News | March 26, 2025
Dr. Leah Pyter details a study which found that chemotherapy induces microbiome disruption and inflammation in BC patients.
Dr. Mik RinneHR Breast Cancer | July 19, 2024
Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.
Carlos Doti, MDBreast Cancer News | March 26, 2025
Carlos Doti, MD, of AstraZeneca, discusses the impact of LYNPARZA over the last decade.
Advertisement